Related Experiment Video
Updated: Nov 20, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A
Sabrina A Assoumou1, Carlos R Sian2, Christina M Gebel3
1Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston Medical Center, 801 Massachusetts Ave., Crosstown Center, 2(nd) Floor, Boston, MA, USA; Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, 801 Massachusetts Ave., Crosstown Center, 2nd Floor, Boston, MA, USA.
Background:
The US opioid crisis is associated with a surge in hepatitis C virus (HCV) infections among persons who inject drugs (PWID), and yet the uptake of HCV curative therapy among PWID is low.
Purpose:
To explore potential solutions to overcome barriers to HCV treatment uptake among individuals at a drug detoxification center.
Methods:
Qualitative study with in-depth interviews and thematic analysis of coded data.
Results:
Patients (N = 24) had the following characteristics: mean age 37 years; 67 % White, 13 % Black, 8 % Latinx, 4 % Native Hawaiian/Pacific Islander, 8 % other; 71 % with a history of injecting drugs. Most patients with a positive HCV test had not pursued treatment due to few perceived immediate consequences from a positive test and possible complications arising in a distant poorly imagined future. Active substance use was a major barrier to HCV treatment uptake because of disruptions to routine activities. In addition, re-infection after treatment was perceived as inevitable. Patients had suggestions to improve HCV treatment uptake: high-intensity wraparound care characterized by frequent interactions with supportive services; same-day/walk-in options; low-barrier access to substance use treatment; assistance with navigating the health care system; attention to immediate needs, such as housing; and the opportunity to select an approach that best fits individual circumstances.
Conclusions:
Active substance use was a major barrier to treatment initiation. To improve uptake, affected individuals recommended that HCV treatment be integrated within substance use treatment programs. Such a model should incorporate patient education within low-barrier, high-intensity wraparound care, tailored to patients' needs and priorities.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Dependence
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

